(PDF) P1.03-007 a Real-World Study of Clinicopathological

P1.03-007 a Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2017.09.811

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

November 1, 2017

Authors

Publisher

Elsevier BV

Related search

Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Rearrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients

Cancer Biology and Therapy

Cancer Research

Molecular Medicine

English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.03-04 Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer

Thoracic Cancer

Respiratory Medicine

English

P1.01-01 ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea

Journal of Thoracic Oncology

Respiratory Medicine

English

Real‐world Progression, Treatment, and Survival Outcomes During Rapid Adoption of Immunotherapy for Advanced Non–small Cell Lung Cancer

Cancer Research

English

Pcn60 - Real-World Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: Results of a Claims Data Study of Patients in Germany

Value in Health

Occupational Health

English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Multidisciplinary

English